ArticleFrontiers in oncology2025
Circ_0060927 regulates miR-331-3p/ERK/MAPK pathway reaction in non-small cell lung cancer through METTL14-driven methylation.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-coding RNA is one of the most paramount genetic regulators. circRNAs (Circular RNAs) are a potential modulator of various tumors, especially in non-small cell lung cancer (NSCLC). This study focused on elucidating the underlying influence of circ_0060927 on NSCLC progression and relevant regulatory mechanisms. Methods: Manipulating circ_0060927, MAP2K7, and METTL14 expression in NSCLC cells by lentiviral vectors. The expression of MAP2K7, ERK, p-ERK, p38MAPK, and p-p38MAPK was measured by RT-qPCR and Western Blot experiments. RIP-RT-qPCR was performed to quantify the m6A methylation status of circ_0060927. Cell Counting Kit-8, cell apoptosis assay, wound healing assay, and transwell assay were employed to identify the discrepancy of tumor cells' malignant phenotypes, including cell proliferation, cell motility, and apoptosis. Results: L78 and A549 cells showed high expression of circ_0060927 and its 6A methylation level compared to normal lung epithelial cells. Circ_0060927 could promote tumor cells' proliferation and motility, and reduce cell apoptosis. These effects depended on the m6A methylation derived from METTL14. Besides, circ_0060927 combined miR-331-3p specifically in NSCLC cells to repress its function; simultaneously, miR-331-3p impeded NSCLC cells through suppressing the ERK/MAPK pathway activation by interfering with the expression of MAP2K7 protein. Conclusions: Circ_0060927 positively regulates NSCLC cells' malignant biological behaviors via targeted binding to miR-331-3p. MiR-331-3p could be recognized as a promising inhibitor for the ERK/MAPK signal pathway in NSCLC cells since it has an interfering effect on MAP2K7 protein. These results cast a meaningful insight into the shadow regarding molecular mechanisms underlying NSCLC and the potential therapeutic perspective of circRNA methylation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.